5/20
01:53 pm
ptn
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
5/15
07:49 am
ptn
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/15
07:30 am
ptn
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
High
Report
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
5/9
07:30 am
ptn
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
High
Report
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
5/2
07:44 am
ptn
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity [Yahoo! Finance]
Low
Report
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity [Yahoo! Finance]
5/2
07:30 am
ptn
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Medium
Report
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
4/30
07:30 am
ptn
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Medium
Report
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
4/8
07:40 am
ptn
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 [Yahoo! Finance]
Low
Report
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 [Yahoo! Finance]
4/8
07:30 am
ptn
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
High
Report
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024